Wordt geladen...
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
Histone deacetylase inhibitors such as vorinostat enhance gemtuzumab ozogamicin efficacy in vitro. We, therefore, investigated vorinostat+gemtuzumab ozogamicin for adults aged 60 years and over with untreated acute myeloid leukemia. We stratified patients into 2 groups (group 1: patients aged ≥70 ye...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Ferrata Storti Foundation
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3342977/ https://ncbi.nlm.nih.gov/pubmed/22133771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.055822 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|